TG Therapeutics (NASDAQ:TGTX) was downgraded by investment analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a research note issued to investors on Tuesday, The Fly reports.

TGTX has been the subject of several other reports. ValuEngine lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of TG Therapeutics in a report on Tuesday, August 7th. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. Finally, BidaskClub lowered shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $31.00.

TG Therapeutics stock traded down $3.15 during midday trading on Tuesday, hitting $6.10. The stock had a trading volume of 206,525 shares, compared to its average volume of 1,249,325. The firm has a market capitalization of $745.37 million, a price-to-earnings ratio of -3.32 and a beta of 1.16. TG Therapeutics has a 52-week low of $7.25 and a 52-week high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 177.79% and a negative net margin of 97,412.51%. analysts predict that TG Therapeutics will post -2.19 EPS for the current fiscal year.

In other TG Therapeutics news, CFO Sean A. Power sold 47,191 shares of the company’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $13.21, for a total value of $623,393.11. Following the completion of the transaction, the chief financial officer now directly owns 473,267 shares in the company, valued at approximately $6,251,857.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 15.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in TG Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 54,587 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 8,435 shares during the period. Quantitative Systematic Strategies LLC bought a new position in TG Therapeutics in the 2nd quarter worth approximately $146,000. RA Capital Management LLC boosted its stake in TG Therapeutics by 73.1% in the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock worth $56,266,000 after purchasing an additional 1,806,452 shares during the period. Highland Capital Management LP boosted its stake in TG Therapeutics by 1.0% in the 2nd quarter. Highland Capital Management LP now owns 469,241 shares of the biopharmaceutical company’s stock worth $6,171,000 after purchasing an additional 4,850 shares during the period. Finally, Opaleye Management Inc. boosted its stake in TG Therapeutics by 127.9% in the 2nd quarter. Opaleye Management Inc. now owns 625,000 shares of the biopharmaceutical company’s stock worth $8,218,000 after purchasing an additional 350,800 shares during the period. Institutional investors and hedge funds own 48.99% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Recommended Story: Stock Symbol

The Fly

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.